Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Olaparib vs Durvalumab in Stage IV NSCLC (ORION)
NCT03775486Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2018
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of olaparib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Dec 2018; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03775486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03775486.